Dr. Paul Spagnuolo and his team at the University of Guelph were studying plant compounds when they stumbled upon something extraordinary: a substance derived from jojoba, a desert shrub best known for moisturizing skin, could selectively kill one of the most aggressive forms of blood cancer. In a study published in the journal Blood, the researchers revealed that acute myeloid leukemia (AML) cells depend on a rigid metabolic pathway—breaking down a specific fat via peroxisomes—to survive, unlike healthy cells that can switch fuel sources. This inflexibility, the team discovered, is governed by a protein called ABCD1, which is produced at abnormally high levels in AML cells.
"Think of it like a fuel system," Spagnuolo explains. "Healthy cells are hybrid cars that can switch energy sources. Leukemia cells, on the other hand, are locked into one fuel type to survive." The breakthrough came when his team developed a jojoba-derived compound that blocks ABCD1, effectively shutting down the cancer’s fuel intake. Without the ability to process these fats, the leukemia cells accumulate toxic levels of lipids and die—a process known as lipotoxicity. Crucially, healthy blood cells remained unharmed, adapting by switching to alternative energy sources.
This selectivity is the holy grail of cancer therapy: destroying malignant cells while sparing healthy ones. The compound, synthesized from jojoba oil, marks the first known inhibitor of peroxisomal fatty acid oxidation in cancer cells. In preclinical models, treatment led to reduced leukemia burden and extended survival, with no major side effects observed. While still years from human trials, the findings open a new front in the fight against AML, a disease that affects over 20,000 Americans annually and has seen limited therapeutic advances in decades.
Spagnuolo’s lab, rooted in food science, has long explored plant-based nutraceuticals as cancer treatments. His prior work on an avocado-derived compound showed similar promise, reinforcing the idea that agricultural research can yield powerful medical insights. But he is quick to clarify: this isn’t about diet. "This research is not about nutrition changes," he emphasizes. "It does not suggest that eating certain foods can treat or prevent leukemia. Instead, it represents a promising direction for future drug development."
Even more exciting is the potential beyond AML. Other cancers, including certain brain and ovarian tumors, also rely on peroxisomal metabolism. If this Achilles’ heel proves common across malignancies, jojoba-inspired therapies could one day reach far beyond blood cancer. For now, the team is refining the compound for stability and potency, aiming to bring it closer to clinical testing. In a world where cancer treatments often come with brutal trade-offs, a gentle desert plant may hold a surprisingly precise weapon.